Mavengity Expands into B2B Research
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the ArticleThe FDA approved Ultragenyx's Fayuvi, the first therapy for the fatal childhood disorder, on the strength of a single-arm trial compared against a natural history cohort, with the clearest benefit in children treated before regression.
An Eighth Circuit panel heard Republican arguments to revive Missouri's 2025 congressional map, but the Supreme Court's stay and the Friday military-ballot deadline make the real decision a race against the calendar.
A new SEC order lets trading venues issue tokenized versions of publicly traded U.S. stocks under a five-year exemption, with dividend and voting rights attached, two days after the Clarity Act failed in the Senate.
The Phase 2 ASTRALS trial of VHB937 missed both endpoints in 251 people with early ALS, ending the TREM2-targeting program and marking Novartis's fourth clinical setback in under a month.
The FDA held a public workshop on testosterone therapy for menopausal women as prescriptions surged 146 percent in three years, and the central question is what evidence would be enough for the first approved product.
The average 30-year fixed mortgage rate rose 19 basis points this week to 6.95 percent, the market's fast repricing after the Federal Reserve's first hike in three years, and buyers are now credit-checked against the new level.
Jyske Realkredit opened a 5 percent fixed-rate mortgage for the first time since December 2023 as rising oil prices, inflation expectations, and U.S. rates pushed the long-running 4 percent loan toward closure.
The U.S. Attorney's Office in Oregon announced more than $314 million recovered from pandemic relief fraud, roughly a fifth of the $1.6 billion in alleged losses, as a national push races the statutes of limitations.
A 709-child trial published in the New England Journal of Medicine found that swapping two chemotherapy blocks for the immunotherapy blinatumomab nearly halved relapses while cutting severe infections from 69 to 24 percent.
Non-English intent signal is still under twenty percent of total volume industrywide, which means most platforms are seeing a fraction of the buying activity happening outside English language markets.
One vendor is explicitly competing on restraint, arguing that a plausible AI generated article that is subtly wrong is worse for a knowledge base than no article at all.
Forrester's own buyer guidance undercuts the AI pitch: providers are getting measurably more efficient, and there is little evidence yet that any of that efficiency is reaching customer pricing.
Forrester's guidance to buyers is blunt: having a data centre in the EU answers one sovereignty question out of four, and most vendor pitches stop at the first.
Forrester frames 2026's binding constraint as a workforce that cannot be trained fast enough, which makes this a services category built around people more than platforms.
Generative AI should have commoditized this category, and instead Forrester's criteria count kept climbing, because the moat was always licensed source access, not summarization.
Two of the category's most prominent independent players are now owned by the card networks they were supposed to route around.
Forrester's provider count nearly doubled in three years, and every other technology category in this series points at the same root cause: the software works and the organisation does not change.
Every reference customer for one vendor said they would buy again, which in PLM can mean genuine excellence or a customer base that has nowhere else to go once the evidence chain is built.
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the ArticleWith James now writing full time for our Healthcare & Medical desk, Mavengity has formally expanded into dedicated medical authorship.
Read the ArticleEvery article on Mavengity is written by a dedicated topic desk and checked against current market practice.
Home, auto, life, and health coverage, explained clearly and checked against the fine print.
Browse InsuranceRates, refinancing, and first-time buyer strategy, without the jargon lenders assume you already know.
Browse MortgageBudgeting, saving, and everyday money habits that compound. No get-rich-quick promises.
Browse Personal FinanceContracts, consumer rights, and disputes, explained so you know where you stand.
Browse LegalHealth coverage and medical billing, broken down so surprise bills are less likely to surprise you.
Browse HealthcareGartner and Forrester categories for B2B, translated into plain-English analysis for buyers, not analyst-subscription holders.
Browse ResearchWe start from public rate filings, regulator guidance, and lender disclosures, not marketing copy.
If a term needs a footnote, we explain it in the sentence instead of hiding it in the fine print.
We flag trade-offs and blind spots, not just the upside, so you get the full picture before you decide.
Mavengity is reader-supported and editorially independent from the products we cover.